Association between the plasma levels of TNF-α, IFN-γ, IL-10, nitric oxide and specific IgG isotypes in the clinical forms of chronic Chagas disease;Associação entre os níveis plasmáticos de TNF-α, IFN-γ, IL-10, óxido nítrico e os isotipos de IgG específicos nas formas clínicas da doença de Chagas crônica

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 42, Issue 4, 2009, Pages 425-430

  Pissetti, Cristina Wide ^a   Correia, Dalmo ^a   Braga, Tárcio Teodoro ^a   Faria, Gladstone Eustáquio Lima ^a   De Oliveira, Rafael Faria ^a   Ribeiro, Betânia Maria ^a   Rodrigues, Denise Bertulucci Rocha ^a,b   Rodrigues, Virmondes ^a  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

^b UNIVERSITY OF UBERABA   (Brazil)

Author keywords

Chagas disease; IFN ; IL 10; Immunoglobulins; Nitric oxide; TNF

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERLEUKIN 10; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMPORT DISEASE; MAJOR CLINICAL STUDY; SOUTH AND CENTRAL AMERICA; TRYPANOSOMA CRUZI;

CASE-CONTROL STUDIES; CHAGAS DISEASE; CHRONIC DISEASE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA;

TRYPANOSOMA CRUZI;

EID: 70349897726     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822009000400013     Document Type: Article

References (27)

1. Abrahamsohn IA, Coffman RL. Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection. Experimental parasitology 84: 231-244, 1996.
2. Brener Z. Pathogenesis and immunopathology of chronic Chagas' disease. Memórias do Instituto Oswaldo Cruz 82: 205-213, 1987.
3. Chagas, C. Nova tripanozomiaze humana. Memórias do Instituto Oswaldo Cruz 1: 159-218, 1909.
4. Consenso Brasileiro em Doença de Chagas. Revista da Sociedade Brasileira de Medicina. Tropical. 38: 12-18, 2005.
5. D'Avila DA, Guedes PM, Castro AM, Gontijo ED, Chiari E, Galvão LM. Immunological imbalance between IFN-gamma and IL-10 levels in the sera of patients with the cardiac form of Chagas disease. Memórias do Instituto Oswaldo Cruz 104: 100-105, 2009.
6. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin América: a review. Memórias do Instituto Oswaldo Cruz 97: 603-612, 2002.
7. Ferreira RC, Ianni BM, Abel LC, Buck P, Mady C, Kalil J, Cunha-Neto E. Increased plasma levels of tumor necrosis factor-alpha in asymptomatic/ "indeterminate" and Chagas disease cardiomyopathy patients. Memórias do Instituto Oswaldo Cruz 98: 407-411, 2003. (Pubitemid 38030560)
8. Gazzinelli RT, Oswald IP, Hieny S, James SL, Sher A. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. European Journal of Immunology 22: 2501-2506, 1992.
9. Hölscher C, Köhler G, Müller U, Mossmann H, Schaub GA, Brombacher F. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infection and Immunity 63: 1208-1215, 1998.
10. I Reunião de Pesquisa Aplicada em Doença de Chagas. Validade do conceito de forma indeterminada de doença de Chagas. Revista da Sociedade Brasileira de Medicina. Tropical 18: 46, 1985.
11. Krettli AU, Brener Z. Protective effects of specific antibodies in Trypanosoma cruzi infections. Journal of immunology 116: 755-760, 1976.
12. Macedo AM, Machado CR, Oliveira RP, Pena SD. Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Memórias do Instituto Oswaldo Cruz 99: 1-12, 2004.
13. Martins GA, Cardoso MA, Aliberti JC, Silva JS. Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice. Immunology Letters 63: 113-120, 1998.
14. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and trasnfusional transmission in the southern cone countries. Memórias do Instituto Oswaldo Cruz 98: 577-591, 2003. (Pubitemid 38019577)
15. Morgan J, Colley DG, Pinto Dias JC, Gontijo ED, Bahia-Oliveira L, Correa-Oliveira R, Powell MR. Analysis of anti-Trypanosoma cruzi antibody isotype specificities by western blot in sera from patients with different forms of Chagas' disease. The Journal of Parasitology 84: 641-643, 1998.
16. Morgan J, Dias JC, Gontijo ED, Bahia-Oliveira L, Correa-Oliveira R, Colley DG, Powell MR. Anti-Trypanosoma cruzi antibody isotype profiles in patients with different clinical manifestations of Chagas' disease. The American Journal of Tropical Medicine and Hygiene 55: 355-359, 1996.
17. Pérez-Fuentes R, López-Colombo A, Ordóñez- Toquero G, Gomez-Albino I, Ramos J, Torres-Rasgado E, Salgado-Rosas H, Romero-Díaz M, Pulido-Pérez P, Sánchez-Guillén MC. Correlation of the serum concentrations of tumour necrosis factor and nitric oxide with disease severity in chronic Chagas disease (American trypanosomiasis). Annals of Tropical Medicine and Parasitology 101: 123-132, 2007.
18. Reed SG. In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. Journal of Immunology 140: 4342-4347, 1988.
19. Ribeiro BM, Crema E, Rodrigues V. Analysis of the cellular immune response in patients with the digestive and indeterminate forms of Chagas' disease. Human Immunology 69: 484-489, 2008.
20. Rocha-Rodrigues DB, Correia D, Marra MD, Giraldo LER, Lages-Silva E, Silva-Vergara ML, Barata CH, Rodrigues V. Cytokine serum levels in patients infected by human immunodeficiency virus with and without Trypanosoma cruzi coinfection. Revista da Sociedade Brasileira de Medicina Tropical 38: 483-487, 2006.
21. Schofield CJ, Jannin J, Salvatella R. The future of Chagas disease control. Trends in Parasitology 22: 583-588, 2006.
22. Silva JS, Morrissey PJ, Grabstein KH, Mohler KM, Anderson D, Reed SG. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. The Journal of Experimental Medicine 175: 169-174, 1992.
23. Silva JS, Vespa GN, Cardoso MA, Aliberti JC, Cunha FC. Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infection and Immunity 63: 4862-4867, 1995.
24. Starobinas N, Russo M, Minoprio P, Hontebeyrie-Joskowicz M. Is TNF alpha involved in early susceptibility of Trypanosoma cruzi-infected C3H/He mice? Research in Immunoloy 142: 117-122, 1991.
25. Talvani A, Rocha MO, Barcelos LS, Gomes YM, Ribeiro AL, Teixeira MM. Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. Clinical Infectious Diseases 38: 943-950, 2004. (Pubitemid 38457201)
26. Tarleton RL. Tumour necrosis factor (cachectin) production during experimental Chagas disease. Clinical and Experimental Immunology 73: 186-190, 1988. (Pubitemid 18199537)
27. Vespa GN, Cunha FQ, Silva JS. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infection and Immunity 62: 5177-5182, 1994.